Ascendis Pharma A/S (ASND) Set to Announce Quarterly Earnings on Thursday

Ascendis Pharma A/S (NASDAQ:ASND) is scheduled to announce its earnings results on Thursday, April 25th.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) EPS for the quarter, beating the consensus estimate of ($2.15) by $0.49. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. The firm had revenue of $148.62 million during the quarter, compared to analyst estimates of $97.02 million. On average, analysts expect Ascendis Pharma A/S to post $-4 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ascendis Pharma A/S Trading Up 1.9 %

ASND stock opened at $144.83 on Wednesday. The stock has a 50-day moving average price of $149.15 and a two-hundred day moving average price of $125.48. Ascendis Pharma A/S has a 12-month low of $66.03 and a 12-month high of $161.00. The company has a market cap of $8.43 billion, a PE ratio of -15.66 and a beta of 0.50.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ASND shares. Citigroup upped their target price on Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a “buy” rating in a research report on Thursday, February 8th. JPMorgan Chase & Co. upped their price objective on Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a research note on Tuesday, April 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $173.00 price objective on shares of Ascendis Pharma A/S in a research note on Thursday, April 18th. Wells Fargo & Company increased their price target on Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $116.00 price objective on shares of Ascendis Pharma A/S in a report on Monday. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.25.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.